FDA Clarifies Next-Generation Heart Drug Expectations

Washington Drug Letter
The FDA says developers of next-generation heart drugs, known as PCSK9 inhibitors, will need to present data showing only their effectiveness at lowering cholesterol, blood pressure and inflammation, not reducing heart attack or stroke.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00